Related Experiment Videos
Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study
L E Visser1, B H Stricker, J van der Velden
1Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences, The Netherlands.
Journal of Clinical Epidemiology
|June 1, 1995
Summary
Angiotensin converting enzyme (ACE) inhibitors increase the risk of coughing, particularly in women. This population-based study confirms ACE inhibitor-induced cough in real-world settings.
Area of Science:
- Pharmacology
- Clinical Medicine
- Epidemiology
Background:
- Cough is a known adverse reaction to Angiotensin Converting Enzyme (ACE) inhibitors.
- The real-world incidence and risk factors for ACE inhibitor-induced cough require further investigation.
Purpose of the Study:
- To determine the risk of coughing as an adverse reaction to ACE inhibitors in a large population.
- To investigate if this adverse effect is more prevalent in women.
Main Methods:
- A population-based case-control study was conducted.
- Data were collected from 161 Dutch general practitioners, including 2436 patients with new-onset cough and 7348 controls.
- Exclusion criteria included pre-existing respiratory conditions or infections.
Main Results:
- Patients experiencing cough were 3.6 times more likely to have been exposed to ACE inhibitors (OR 2.5 after adjustment).
- The adjusted odds ratio for cough was higher in females (2.7) compared to males (1.8).
Conclusions:
- ACE inhibitors are associated with an increased risk of developing cough.
- Women appear to be at a higher risk for this adverse effect.